NO20064274L - 8-hydroksy-5-[(-hydroksy-2[[ (1R)-2-(4-metoksyfenyl)-1-metylyletyl] amino][etyl]-2(1H)-quinolinon monohydroklond i krystallinsk form og fremgangsmaten for dens fremstilling - Google Patents
8-hydroksy-5-[(-hydroksy-2[[ (1R)-2-(4-metoksyfenyl)-1-metylyletyl] amino][etyl]-2(1H)-quinolinon monohydroklond i krystallinsk form og fremgangsmaten for dens fremstillingInfo
- Publication number
- NO20064274L NO20064274L NO20064274A NO20064274A NO20064274L NO 20064274 L NO20064274 L NO 20064274L NO 20064274 A NO20064274 A NO 20064274A NO 20064274 A NO20064274 A NO 20064274A NO 20064274 L NO20064274 L NO 20064274L
- Authority
- NO
- Norway
- Prior art keywords
- hydroxy
- methoxyphenyl
- ethyl
- amino
- crystalline form
- Prior art date
Links
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title abstract 2
- GLGOVIORUDCBHW-UHFFFAOYSA-N 1-ethylquinolin-2-one hydrochloride Chemical compound Cl.C(C)N1C(C=CC2=CC=CC=C12)=O GLGOVIORUDCBHW-UHFFFAOYSA-N 0.000 title 1
- 239000000969 carrier Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04007045 | 2004-03-24 | ||
PCT/EP2005/003144 WO2005089760A1 (en) | 2004-03-24 | 2005-03-24 | 8-hydroxy-5-[(-hydroxy-2-[[ (1r)-2-(4-methoxyphenyl)-1-methylethyl] amino ][ethyl] -2(1h)-quinolinone monohydrochloride in crystalline form and the process for its preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20064274L true NO20064274L (no) | 2006-10-13 |
Family
ID=34963779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20064274A NO20064274L (no) | 2004-03-24 | 2006-09-21 | 8-hydroksy-5-[(-hydroksy-2[[ (1R)-2-(4-metoksyfenyl)-1-metylyletyl] amino][etyl]-2(1H)-quinolinon monohydroklond i krystallinsk form og fremgangsmaten for dens fremstilling |
Country Status (30)
Country | Link |
---|---|
US (1) | US20070197586A1 (es) |
EP (1) | EP1729773B1 (es) |
JP (1) | JP2007530489A (es) |
KR (1) | KR20070001946A (es) |
CN (2) | CN1929840B (es) |
AR (1) | AR048339A1 (es) |
AT (1) | ATE399552T1 (es) |
AU (1) | AU2005224032A1 (es) |
BR (1) | BRPI0508213A (es) |
CA (1) | CA2560650A1 (es) |
CY (1) | CY1108323T1 (es) |
DE (1) | DE602005007871D1 (es) |
DK (1) | DK1729773T3 (es) |
EA (1) | EA010128B1 (es) |
ES (1) | ES2309739T3 (es) |
HR (1) | HRP20080495T3 (es) |
IL (1) | IL178227A0 (es) |
MA (1) | MA28549B1 (es) |
MX (1) | MXPA06010515A (es) |
NO (1) | NO20064274L (es) |
NZ (1) | NZ550010A (es) |
PE (1) | PE20060159A1 (es) |
PL (1) | PL1729773T3 (es) |
PT (1) | PT1729773E (es) |
RS (1) | RS50602B (es) |
SI (1) | SI1729773T1 (es) |
TN (1) | TNSN06249A1 (es) |
UA (1) | UA86221C2 (es) |
WO (1) | WO2005089760A1 (es) |
ZA (1) | ZA200607907B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1953143A1 (en) * | 2007-01-30 | 2008-08-06 | CHIESI FARMACEUTICI S.p.A. | Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride |
EP2116537A1 (en) | 2008-05-07 | 2009-11-11 | CHIESI FARMACEUTICI S.p.A. | Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride |
EP2116536A1 (en) | 2008-05-07 | 2009-11-11 | CHIESI FARMACEUTICI S.p.A. | Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride |
WO2011015289A1 (en) | 2009-08-04 | 2011-02-10 | Chiesi Farmaceutici S.P.A. | 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate |
EP2360147A1 (en) | 2010-02-22 | 2011-08-24 | CHIESI FARMACEUTICI S.p.A. | Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8334494D0 (en) * | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
GB9603237D0 (en) * | 1996-02-16 | 1996-04-17 | Sandoz Ltd | Organic compounds |
SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
CA2534693A1 (en) * | 2003-08-05 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising steroids and a betamimetic |
EP1953143A1 (en) * | 2007-01-30 | 2008-08-06 | CHIESI FARMACEUTICI S.p.A. | Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride |
EP2116537A1 (en) * | 2008-05-07 | 2009-11-11 | CHIESI FARMACEUTICI S.p.A. | Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride |
EP2116536A1 (en) * | 2008-05-07 | 2009-11-11 | CHIESI FARMACEUTICI S.p.A. | Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride |
-
2005
- 2005-03-23 AR ARP050101185A patent/AR048339A1/es not_active Application Discontinuation
- 2005-03-23 PE PE2005000338A patent/PE20060159A1/es not_active Application Discontinuation
- 2005-03-24 DE DE602005007871T patent/DE602005007871D1/de active Active
- 2005-03-24 UA UAA200609448A patent/UA86221C2/uk unknown
- 2005-03-24 DK DK05730069T patent/DK1729773T3/da active
- 2005-03-24 ES ES05730069T patent/ES2309739T3/es active Active
- 2005-03-24 EP EP05730069A patent/EP1729773B1/en active Active
- 2005-03-24 CN CN2005800076387A patent/CN1929840B/zh not_active Expired - Fee Related
- 2005-03-24 WO PCT/EP2005/003144 patent/WO2005089760A1/en active Application Filing
- 2005-03-24 KR KR1020067015966A patent/KR20070001946A/ko not_active Application Discontinuation
- 2005-03-24 JP JP2007504359A patent/JP2007530489A/ja not_active Withdrawn
- 2005-03-24 CA CA002560650A patent/CA2560650A1/en not_active Abandoned
- 2005-03-24 NZ NZ550010A patent/NZ550010A/en unknown
- 2005-03-24 CN CN200910173473A patent/CN101812017A/zh active Pending
- 2005-03-24 EA EA200601531A patent/EA010128B1/ru not_active IP Right Cessation
- 2005-03-24 US US10/593,571 patent/US20070197586A1/en not_active Abandoned
- 2005-03-24 MX MXPA06010515A patent/MXPA06010515A/es active IP Right Grant
- 2005-03-24 AU AU2005224032A patent/AU2005224032A1/en not_active Abandoned
- 2005-03-24 PL PL05730069T patent/PL1729773T3/pl unknown
- 2005-03-24 RS RSP-2008/0393A patent/RS50602B/sr unknown
- 2005-03-24 AT AT05730069T patent/ATE399552T1/de not_active IP Right Cessation
- 2005-03-24 SI SI200530320T patent/SI1729773T1/sl unknown
- 2005-03-24 PT PT05730069T patent/PT1729773E/pt unknown
- 2005-03-24 BR BRPI0508213-7A patent/BRPI0508213A/pt not_active IP Right Cessation
-
2006
- 2006-08-04 TN TNP2006000249A patent/TNSN06249A1/en unknown
- 2006-09-21 ZA ZA2006/07907A patent/ZA200607907B/en unknown
- 2006-09-21 IL IL178227A patent/IL178227A0/en not_active IP Right Cessation
- 2006-09-21 NO NO20064274A patent/NO20064274L/no not_active Application Discontinuation
- 2006-10-23 MA MA29409A patent/MA28549B1/fr unknown
-
2008
- 2008-09-04 CY CY20081100962T patent/CY1108323T1/el unknown
- 2008-10-01 HR HR20080495T patent/HRP20080495T3/xx unknown
Also Published As
Publication number | Publication date |
---|---|
US20070197586A1 (en) | 2007-08-23 |
WO2005089760A1 (en) | 2005-09-29 |
EP1729773A1 (en) | 2006-12-13 |
NZ550010A (en) | 2010-08-27 |
CN1929840B (zh) | 2010-12-08 |
ZA200607907B (en) | 2008-04-30 |
EA200601531A1 (ru) | 2007-04-27 |
BRPI0508213A (pt) | 2007-07-17 |
HRP20080495T3 (en) | 2008-11-30 |
AR048339A1 (es) | 2006-04-19 |
MXPA06010515A (es) | 2007-03-30 |
EA010128B1 (ru) | 2008-06-30 |
CN101812017A (zh) | 2010-08-25 |
DK1729773T3 (da) | 2008-10-20 |
PL1729773T3 (pl) | 2008-12-31 |
KR20070001946A (ko) | 2007-01-04 |
UA86221C2 (en) | 2009-04-10 |
CA2560650A1 (en) | 2005-09-29 |
PE20060159A1 (es) | 2006-04-04 |
CY1108323T1 (el) | 2014-02-12 |
TNSN06249A1 (en) | 2007-12-03 |
MA28549B1 (fr) | 2007-04-03 |
PT1729773E (pt) | 2008-09-29 |
IL178227A0 (en) | 2006-12-31 |
EP1729773B1 (en) | 2008-07-02 |
SI1729773T1 (sl) | 2008-10-31 |
CN1929840A (zh) | 2007-03-14 |
DE602005007871D1 (de) | 2008-08-14 |
ATE399552T1 (de) | 2008-07-15 |
ES2309739T3 (es) | 2008-12-16 |
AU2005224032A1 (en) | 2005-09-29 |
RS50602B (sr) | 2010-05-07 |
JP2007530489A (ja) | 2007-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8633219B2 (en) | Combination therapy | |
LU92602I2 (fr) | Trametinib, optionnellement sous la forme d'un sel, hydrate ou solvate pharmaceutiquement acceptablede celui-ci | |
AU2012243329A8 (en) | 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use | |
FI4159217T3 (fi) | Mek-estäjän ja b-raf-estäjän käsittävä yhdistelmä | |
RS20050615A (en) | Medicamentt comprising a highly long-lasting beta2-agonist in combination with other active ingredients | |
WO2008054454A3 (en) | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | |
WO2009049180A3 (en) | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels | |
WO2006011050A3 (en) | Pyridine derivatives | |
TW200626601A (en) | Novel compounds | |
WO2007041130A3 (en) | Deazapurines useful as inhibitors of janus kinases | |
WO2007120647A3 (en) | Compositions useful as inhibitors of voltage-gated sodium channels | |
IL176416A (en) | History of Nitroxy prostaglandin, pharmaceutical preparations containing them, and their use in the preparation of the drug for the treatment of glaucoma or intraocular pressure | |
WO2007014940A3 (en) | Quinoline derivatives as antibacterical agents | |
WO2007062999A3 (en) | 1,5-substituted indol-2-yl amide derivatives | |
EP2650293A8 (en) | [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof | |
NO20064274L (no) | 8-hydroksy-5-[(-hydroksy-2[[ (1R)-2-(4-metoksyfenyl)-1-metylyletyl] amino][etyl]-2(1H)-quinolinon monohydroklond i krystallinsk form og fremgangsmaten for dens fremstilling | |
WO2002102793A3 (en) | Quinazolinediones as antibacterial agents | |
WO2008010238A3 (en) | Antidiabetic azabicyclo [3. 1. 0] hexan compounds | |
WO2004094386A8 (en) | Isoquinoline-5-sulfonic acid amides as inhibitors of akt (protein kinase b) | |
WO2005075450A3 (en) | Spiro-benzodioxoles and their use as cb1 antagonists | |
WO2007126900A3 (en) | Antifungal agents | |
WO2005090287A3 (en) | Phenylethanolamine derivatives as beta-2 agonists | |
WO2006103545A8 (en) | 4-piperazinylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors | |
AR054888A1 (es) | Derivados de quinolina como agentes antibacterianos | |
EA200800154A1 (ru) | Производные хинолина в качестве антибактериальных средств |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |